Gynaecologia et Perinatologia; Vol.12 No.3 01/2003;
Source: OAI


By comprehending that unopposed estrogens, both of endogenous or exogenous origin, increase the emergence¬ risk of endometrial cancer, the application of progesterone has begun exclusively for the purpose of preserving the health of endometrium. Natural progesterone, because of its quick metabolism in the liver and intestines, low absorption and low bioavailability in the serum, could not be used for that purpose. Therefore, more powerful synthetic progesterones, gestagens,¬ have been synthetized which have a good effect on the endometrium and protect it from unopposed activity of estrogens. But, time has shown that synthetic gestagens can have harmful effect on the metabolism of glucose, lipoproteins in plasma,¬ endothel of blood vessels and the terathogenic effect on the fetus is also possible. By determining the chemical structure and classification of gestagens according to affinity for binding with different receptors¬ the efficiency and possible side-effects of gestagens could not be foreseen with certainty. By micronizing the progesterone, absorption in the intestines and bioavailability in the serum is increased in both oral and vaginal use. Such progesterone preparation has shown good therapeutical effects in patients with premenstrual syndrome,¬ secondary amenorrhaea, as well as in the treatment of infertility, threatening and repeated spontaneous abortions. Considering that, in the mentioned indications, it appeared to be very efficient, without side-effects, its use is recommended instead of unpredictable and sometimes harmful gestagens.

Download full-text


Available from: Branko Radaković, Apr 01, 2014
65 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: To study the effects of exogenous estrogens on the postmenopausal endometrium, and to determine the time course and minimum dosage of added progestins necessary to oppose estrogen stimulation, we obtained endometrial specimens from symptomatic postmenopausal women being treated with various preparations of estrogens and progestins. Morphologic changes were assessed with light and electron microscopy, and biochemical effects through measurement of DNA synthesis, estradiol and progesterone receptors, and isocitric and estradiol dehydrogenase activity. For comparison, identical studies were carried out on specimens from premenopausal women in the proliferative and secretory phases of their cycle. All the estrogens exerted stimulatory effects in the postmenopausal specimens that were comparable to those observed in the premenopausal proliferative-phase specimens. Estropipate, subcutaneous estradiol, and conjugated estrogens had some hyperphysiologic effects. Maximal progestational effects occurred in the postmenopausal specimens only after norethindrone was administered for six days, and a constant level of activity equal to that in premenopausal secretory-phase specimens was then observed until the 10th day of exposure. Similar maximal effects occurred after six days of treatment with D/L-norgestrel (150 and 5 mg daily [10 mg daily produced less complete changes]). We conclude that many estrogen preparations subject the endometrium to a potent stimulus. Norethindrone and norgestrel are protective because they counteract the proliferative effects of estrogens, but the currently recommended daily dosages of these progestins can be greatly reduced without loss of response.
    New England Journal of Medicine 01/1982; 305(27):1599-605. DOI:10.1056/NEJM198112313052701 · 55.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Progestin is often added to regimens of estrogen therapy in postmenopausal women to reduce the risk of endometrial hyperstimulation, but it may cause undesirable metabolic effects. Therefore, a low dosage is recommended. At present, the only way to determine whether the dosage of progestin is causing the desired secretory transformation of the endometrium is by endometrial sampling, which is invasive. We studied 102 postmenopausal women undergoing estrogen therapy who also took a progestin for 12 days each month, and we correlated the day of onset of bleeding with the endometrial histology over a three-month period. A bleeding pattern suitable for interpretation was observed in 96 women. Regardless of the preparation and dosage of the estrogen and progestin used, wholly or predominantly proliferative endometrium was always associated with bleeding on or before day 10 after the addition of progestin; wholly or predominantly secretory endometrium, or a lack of endometrial tissue, was associated with bleeding on day 11 or later. We conclude that the bleeding pattern reflected the histologic condition of the endometrium and that adjustment of the dosage of progestin so that regular bleeding is induced on or after day 11 may obviate the need for endometrial biopsy.
    New England Journal of Medicine 11/1986; 315(15):930-4. DOI:10.1056/NEJM198610093151504 · 55.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we report the effects of cyclic hormone replacement therapy on carbohydrate metabolism in six women with premature ovarian failure. Using tolbutamide-modified iv glucose tolerance tests patients were evaluated during three different intervals of their second treatment cycle: no hormone replacement, estradiol-only (E2-only) replacement, and E2-plus-medroxyprogesterone acetate (MPA) replacement. Insulin sensitivity and glucose effectiveness were derived using insulin and glucose levels obtained from tolbutamide-modified iv glucose tolerance tests and analyzed with the minimal model computer program. The mean insulin sensitivity (x 10(-4)/min/ significantly decreased from 4.0 +/- 0.8 during no hormone replacement and 3.8 +/- 0.8 during E2-only replacement to 2.6 +/- 0.5 (x 10(-4)/min/microU/ml) during E2-plus-MPA replacement (P < 0.005). Glucose effectiveness did not change as a function of the phase of hormone replacement therapy. These findings indicate a significant decrease in sensitivity to insulin associated with MPA treatment but no observable change in insulin sensitivity during the E2-only phase of cyclic steroid replacement therapy in young women. Our results support the hypothesis that impairment of insulin-mediated glucose uptake during the luteal phase of the menstrual cycle is due to increased progesterone secretion.
    Journal of Clinical Endocrinology &amp Metabolism 02/1993; 76(2):472-5. DOI:10.1210/jc.76.2.472 · 6.21 Impact Factor
Show more